TPST2: A Potential Drug Target and Biomarker for Transport and Golgi Organization 13 Homolog B

Target Name: TPST2

NCBI ID: G8459

TPST2: A Potential Drug Target and Biomarker for Transport and Golgi Organization 13 Homolog B

Transport and Golgi organization 13 (TGo13) is a protein that plays a crucial role in the organization and delivery of intracellular vesicles, including the endoplasmic reticulum (ER) and the trans-golgi network (TGN). TGo13 is a 13-kDa protein that consists of two distinct domains: an N-terminal cytoplasmic domain and a C-terminal transmembrane domain. The cytoplasmic domain contains a putative ATP-binding site, which may be involved in the regulation of intracellular vesicle delivery. The C-terminal domain is known for its role in the formation of the TGN and has been implicated in the regulation of synaptic vesicle recycling.

Recent studies have identified TGo13 as a potential drug target and biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. These studies have demonstrated that TGo13 levels are altered in these disorders and that modulating TGo13 activity may be a promising strategy for the development of new treatments.

Drug Targeting Strategies

Despite the potential benefits of targeting TGo13, several challenges must be overcome before it can be used as a drug target. One of the major challenges is the lack of structural information about TGo13, which makes it difficult to design small molecules that interact with the protein. To overcome this challenge, researchers have used various techniques, such as yeast two-hybrid, protein fragment complementation, and transcriptional assays, to identify potential binding partners for TGo13.

Another challenge is the potential for TGo13 dysfunction in disease-related processes, which could limit the effectiveness of drug targets. To address this challenge, researchers have used cell-based assays to demonstrate that modulating TGo13 activity can improve the delivery of known cargoes, such as the neurotransmitter acetylcholine, to the ER and the TGN.

Biomarker Development

To develop TGo13 as a biomarker for disease, researchers have used various techniques to measure TGo13 levels in patient samples and compare them to those of healthy controls. These studies have demonstrated that TGo13 levels are altered in a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

In addition, researchers have used techniques such as mass spectrometry and immunofluorescence to demonstrate that TGo13 is involved in the formation of the TGN and that it plays a role in the regulation of synaptic vesicle recycling. These findings suggest that TGo13 may be a promising biomarker for disease and that its dysfunction may contribute to the development of various neurological and psychiatric disorders.

Conclusion

In conclusion, TPST2 (Transport and Golgi organization 13 homolog B) is a protein that is involved in the delivery and organization of intracellular vesicles, including the endoplasmic reticulum and the trans-golgi network. Its dysfunction has been implicated in the development of various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Therefore, TGo13 is a potential drug target and biomarker for these disorders, and its modulation may be a promising strategy for the development of new treatments. Further research is needed to fully understand the role of TGo13 in disease and to develop effective strategies for its modulation.

Protein Name: Tyrosylprotein Sulfotransferase 2

Functions: Catalyzes the O-sulfation of tyrosine residues within acidic motifs of polypeptides, using 3'-phosphoadenylyl sulfate (PAPS) as cosubstrate

More Common Targets